Bioiberica, a global life science company with more than 45 years’ experience in the research, production and commercialisation of molecules of high biological and therapeutic value, proudly presents the latest scientific evidence behind its native (undenatured) type II collagen – Collavant n2.
The women-only study explored the effects of 40 mg/day Collavant n2 supplementation on joint functionality and quality of life in women with knee osteoarthritis (OA), confirming that the ingredient enhanced functionality and joint comfort in six weeks.[1]
This finding adds to the bank of positive clinical evidence surrounding collagen supplementation in the mobility sphere, whilst illuminating the ingredient’s innovation potential in women’s health products specifically.
Fresh scientific insights revealed for Collavant n2
Knee OA involves the gradual degeneration of cartilage – causing joint pain, stiffness and reduced mobility. A randomised controlled clinical trial published in scientific journal, Wiener klinische Wochenschrift (The Central European Journal of Medicine) set out to investigate the impact of Motilex Caps (Apsen Farmaceutica, Brazil) in women with the condition, compared to a control and exercise group.
Motilex Caps is a capsule containing Collavant n2 native (undenatured) type II collagen.* The supplemented group received 40 mg of Collavant n2 once daily for six weeks.
The results demonstrated a 44.8% improvement in WOMAC pain score – indicating enhanced joint comfort; greater range of motion (ROM) in the knee; and a 10.4% increase in the distance walked during six minutes without discomfort. These findings affirm that Collavant n2 supplementation contributes to improved functionality and comfort in women with knee OA.
Positive results were also observed in the exercise group, highlighting potential benefits of combining supplement and exercise interventions for joint health.
New avenues for innovation in women’s health
Joan Bassa, Human Health Business Unit Director at Bioiberica, comments: “These latest clinical conclusions open up new possibilities for innovation with native (undenatured) type II collagen in women’s health, especially during menopause when joint health problems can become a concern due to oestrogen deficiency. Low-dosage, science-backed ingredients that have been shown to support joint health, like Collavant n2, could therefore help to address the needs of women during this life phase.”